Question 1

What amounts of HGH did the published trials use?

Accepted Answer

Three figures carry most of the published record. Each is tied to body weight, so each is a rate rather than a fixed amount in a vial. In the 52-week heiGHt trial, patients were randomized 2:1 to receive lonapegsomatropin 0.24 mg hGH/kg/week or an equivalent weekly dose of somatropin delivered daily. In a separate phase 3 comparison, participants were randomized 1:1 to receive once-weekly somatrogon (0.66 mg/kg/week) or once-daily somatropin (0.24 mg/kg/week) for 12 months. In adults wasting from HIV, somatropin 0.1 mg/kg/day administered subcutaneously for 12 weeks was set against placebo. Those are trial parameters rather than instructions. Each is an amount a trial team picked for a patient whose weight had been taken, in a study built to answer a question about that patient. Cut loose from all of that, the number on its own means very little.

Question 2

Who received those amounts?

Accepted Answer

Everyone in the published record carried a diagnosis, and that is the most important fact on this page. The heiGHt trial enrolled and dosed 161 treatment-naive, prepubertal patients with growth hormone deficiency. The somatrogon comparison took 228 prepubertal children with impaired height and height velocity and no prior growth hormone treatment. The wasting work was done in patients for whom loss of body cell mass, a component of lean body mass, is associated with decreased survival. There is no step from any of those to a healthy adult, and we do not publish one. Nothing among the research behind this page converts an amount set against a diagnosis into an amount for a body making its own growth hormone normally. Read what that means rather than what it sounds like. It is neither a warning nor an all-clear. In the research behind this page, it is the statement that the question has not been asked, so the figures above describe the people who received them and nobody else at all.

Question 3

How many IU of HGH is 1 mg?

Accepted Answer

The documented labels print both measures, and one FDA listing pairs them on a single line by recording a 5 mg (15 IU) 1-count bottle. That is one preparation stating its own strength in two ways. It is not a factor to carry anywhere else. The other labels give milligrams and a volume instead, among them a Norditropin FlexPro Somatropin (rDNA origin) injection, 30 mg/3 mL Prefilled Pen. A vial with no label states nothing at all. So the international-unit questions circulating around growth hormone cannot be settled as arithmetic. The arithmetic needs a labelled strength to start from, and for unlabelled material no source among the research behind this page supplies one, which leaves the question unanswerable rather than merely unanswered.

Question 4

What does 2 IU of HGH a day do?

Accepted Answer

No trial among the research behind this page has given growth hormone as a fixed daily number of international units to a healthy adult, so no result attaches to that figure. Every amount in the record is written per kilogram of body weight, which means a single milligram figure is two different amounts in two different people. The amount also tracks the diagnosis rather than anybody's goal. A 2025 analysis of two large registries records that average dose of GH was higher for children with ISS vs children with GHD but mean duration of treatment was shorter, ISS meaning short stature with no measured shortfall and GHD meaning growth hormone deficiency. Read that carefully, because it shows what such a figure is answering. An amount set against a named condition in a weighed patient is not a quantity anybody can lift out and apply elsewhere, and a daily figure in international units has no measurement standing behind it.

Question 5

Is there an HGH dosage for bodybuilding?

Accepted Answer

No trial among the research behind this page has given growth hormone to a healthy adult for muscle, so there is no amount to report and no schedule to describe. That is the whole of the honest answer, and the useful part of it sits alongside. One approval mentions lean body mass, and it belongs to an illness. A 2006 review records that somatropin derived from mammalian cells is the only US FDA-approved treatment indicated to increase lean body mass, bodyweight and physical endurance in HIV-associated wasting. The amount behind that approval is the per-kilogram daily schedule set out above, run for twelve weeks in patients with that illness. Read the population rather than the outcome. Putting mass back onto a wasting patient and adding mass to a well adult are different questions, and only the first of them has an amount attached to it.

Question 6

Is there an HGH cycle, and do you cycle off?

Accepted Answer

No trial among the research behind this page has tested stopping and restarting growth hormone, so there is no interval to report. The schedules in the record run continuously, for as long as the condition they were written against lasts. What is documented is people stopping altogether, which is a different event. A Japanese claims study defined persistence as continuous refills of somatropin with no gaps in therapy. The same study records that high rates of discontinuation and poor adherence to treatment, which are associated with worse growth outcomes, have been documented previously, for example in the US and Europe. So a gap appears in that record as a failure of continuity rather than as a planned phase. A cycle in the sense the question means, on for a stretch and off for a stretch by design, has never been studied, and nothing among the research behind this page describes what happens across one.

Question 7

How often was it injected, and by what route?

Accepted Answer

Under the skin, on one of two schedules, in every published trial without exception. The newer versions go in once a week. A 2022 review records that the long-acting version is administered as a once-weekly subcutaneous injection. In the six-year extension, participants received subcutaneous injections of lonapegsomatropin dosed at 0.24 mg hGH/kg/week. The older schedule is daily, and the weekly total was matched when the two were set against each other. Nothing among the research behind this page splits a weekly amount across other gaps, tests a different way into the body, or sets one injection site against another. Those are not questions the literature answered badly. They are questions nobody put to it, which is an absence of investigation rather than an absence of effect.

Question 8

How was the amount set and then adjusted?

Accepted Answer

Against a blood measurement, in the children and in the few adults on record alike. A prospective, single-arm, single-center study was conducted in 20 adult GH deficiency participants without diabetes. In it, participants receiving somatropin were switched to a weekly version, with doses titrated over 3 months to maintain IGF-1 levels within plus or minus 2 SD. IGF-1 is insulin-like growth factor 1, the blood signal that rises when growth hormone acts. The children's record shows the same logic running over a longer stretch. In the six-year extension, mean values of weekly average IGF-1 remained within 0-2 SDS throughout the trial, and the dose remained stable throughout the trial. That is a schedule governed by a number taken out of somebody's arm rather than by a target anybody picked. Without that measurement the published record holds no mechanism for setting an amount, and it describes none.

Question 9

What strengths do HGH vials come in?

Accepted Answer

The documented presentations state a strength, and the FDA listings record them exactly. A 2013 entry covers a Nutropin AQ NuSpin 20 pen holding 20 mg/2mL. The same firm's smaller pen, Nutropin AQ NuSpin 10, is listed at 10 mg/2mL. A 2021 entry covers a needle-free delivery device for use with ZOMACTON (somatropin) for injection 5mg vial, Rx only. Those figures are packaging facts rather than amounts anybody was told to use. They matter because concentration is what connects a milligram figure to a volume, and the arithmetic itself sits on the reconstitution calculator. A vial arriving with no strength printed on it breaks that chain at the first step. No source among the research behind this page states what is inside such a vial, so a volume drawn from it corresponds to an unknown amount rather than to a small one.

Question 10

How long did people stay on these amounts?

Accepted Answer

Longer than in most of the trials covered on this site, and always for as long as the diagnosis lasted. The heiGHt trial was a randomized, open-label, active-controlled, 52-week Phase 3 trial, and the somatrogon comparison ran for twelve months. In the six-year extension, growth was maintained throughout pubertal development on an unchanged amount. The registry stretches further in calendar time than any single patient did. Median rhGH treatment duration was 2.7 years and observation 3.1 years across 83,803 children. A 2025 registry analysis describes GH treatment over 5 to 10 years in children with short stature and in children with a deficiency. Nothing among the research behind this page runs past those six years of continuous administration inside a trial. Duration beyond that point is unstudied rather than cleared, and the distance between those two words is the whole of what can honestly be said.

Question 11

Why do the published amounts differ so much?

Accepted Answer

Because the figures belong to different molecules, and the molecules are not interchangeable. A reference entry describes lonapegsomatropin as a long-acting prodrug of somatropin, meaning a form that holds the hormone and lets it go slowly. A weekly figure for it therefore covers seven days of release rather than one injection's worth of hormone. Approved copies of the original add another layer on top. A 2011 review notes that the substitution of one approved copy for another is still a matter of discussion. So a number quoted without its molecule is not a larger or a smaller amount than another number. It is an amount with its meaning stripped off, which is the condition most of the figures circulating about growth hormone are in.

Question 12

Does any of this apply to a vial bought outside a pharmacy?

Accepted Answer

No, and that separation is the point of the whole page. An approved schedule belongs to an approved injection, made by a named firm to a filed specification and dispensed against a diagnosis. The FDA listings carry that on their face, down to a 5 mg (15 IU) bottle marked Prescription Only and distributed by a named firm in Sellersville, Pennsylvania. A vial bought elsewhere carries a chemical name and little else. It states no concentration, so a volume drawn from it matches an unknown amount rather than a small one, and it carries no lot number, so nothing about it can be traced backwards. No analysis among the research behind this page has measured the identity, concentration or sterility of material obtained that way. We do not publish the step across from one to the other, because no study we could find has ever validated that step. What can be checked about a seller and a vial is set out on the buying page.

Trial	Amount studied	Compared with	Length
heiGHt trial	Lonapegsomatropin 0.24 mg hGH/kg/week	Equivalent weekly dose of somatropin, given daily	52 weeks
Phase 3 comparison	Somatrogon 0.66 mg/kg/week	Somatropin 0.24 mg/kg/week, once daily	12 months
Adults wasting from HIV	Somatropin 0.1 mg/kg/day, under the skin	Placebo	12 weeks

HGH protocols in the published literature